Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

被引：0
|
作者：
Bernhard C. Pestalozzi
Christoph Tausch
Konstantin J. Dedes
Christoph Rochlitz
Stefan Zimmermann
Roger von Moos
Ralph Winterhalder
Thomas Ruhstaller
Andreas Mueller
Katharina Buser
Markus Borner
Urban Novak
Catrina Uhlmann Nussbaum
Bettina Seifert
Martin Bigler
Vincent Bize
Simona Berardi Vilei
Christoph Rageth
Stefan Aebi
机构：
[1] Universitaetsspital Zuerich,
[2] Brustzentrum Zuerich,undefined
[3] Universitaetsspital Basel,undefined
[4] Hôpital Cantonal Fribourg,undefined
[5] Kantonsspital Graubuenden Chur,undefined
[6] Luzerner Kantonsspital,undefined
[7] Breast Center St. Gallen,undefined
[8] Kantonsspital Winterthur,undefined
[9] Engeriedspital Bern,undefined
[10] Spitalzentrum Biel,undefined
[11] Inselspital Bern,undefined
[12] Kantonsspital Olten,undefined
[13] Kantonsspital Baselland,undefined
[14] SAKK Coordinating Center,undefined
来源：
BMC Cancer | / 17卷
关键词：
ER-positive early breast cancer; Adjuvant treatment recommendation; Multigene expression profiling; Recurrence score; Oncotype DX;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer
    Ueno, Takayuki
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [22] 21-gene recurrence score® in patients with primary metastatic ER+HER2-breast cancer
    Barinoff, J.
    Anastasiadou, L.
    Brandi, C.
    Junker-Stein, A.
    Silbermann, J.
    Langenfeld, M.
    Fortmann, C.
    Thill, M.
    CANCER RESEARCH, 2017, 77
  • [23] The 21-Gene Recurrence Score Influences Treatment Recommendations for Patients With Node-Positive Breast Cancer
    Millien, Jeffanne
    Edwards, Claire
    Kaltman, Rebecca
    McSwain, Anita P.
    McGrail, Lisa
    Teal, Christine B.
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 : 82 - 83
  • [24] Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
    Bae, Soong June
    Ahn, Sung Gwe
    Ji, Jung Hwan
    Chu, Chihhao
    Kim, Dooreh
    Lee, Janghee
    Cha, Yoon Jin
    Jeong, Joon
    CANCERS, 2021, 13 (16)
  • [25] First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
    Dieci, Maria Vittoria
    Guarneri, Valentina
    Giarratano, Tommaso
    Mion, Marta
    Tortora, Giampaolo
    De Rossi, Costanza
    Gori, Stefania
    Oliani, Cristina
    Merlini, Laura
    Pasini, Felice
    Bonciarelli, Giorgio
    Griguolo, Gaia
    Orvieto, Enrico
    Michieletto, Silvia
    Saibene, Tania
    Del Bianco, Paola
    De Salvo, Gian Luca
    Conte, PierFranco
    ONCOLOGIST, 2018, 23 (03): : 297 - 305
  • [26] Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer
    Dowsett, Mitch
    Sestak, Ivana
    Buus, Richard
    Lopez-Knowles, Elena
    Mallon, Elizabeth
    Howell, Anthony
    Forbes, John F.
    Buzdar, Aman
    Cuzick, Jack
    CLINICAL CANCER RESEARCH, 2015, 21 (12) : 2763 - 2770
  • [27] Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center
    Salah Fayaz
    Heba El-Sayed Eissa
    Gerges Attia Demian
    Journal of the Egyptian National Cancer Institute, 32
  • [28] Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center
    Fayaz, Salah
    Eissa, Heba El-Sayed
    Demian, Gerges Attia
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2020, 32 (01)
  • [29] The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use
    Eiermann, W.
    Rezai, M.
    Kuemmel, S.
    Kuehn, T.
    Warm, M.
    Friedrichs, K.
    Schneeweiss, A.
    Markmann, S.
    Eggemann, H.
    Hilfrich, J.
    Jackisch, C.
    Witzel, I.
    Eidtmann, H.
    Bachinger, A.
    Hell, S.
    Blohmer, J.
    ANNALS OF ONCOLOGY, 2013, 24 (03) : 618 - 624
  • [30] The impact of 21-Gene Recurrence Score test and classic clinical-pathologic factors in guiding adjuvant therapy for HER-2 negative, ER-positive, early-stage breast cancer: A retrospective study
    Rodriguez Palleiro, Maria Clara
    Krygier Waltier, Gabriel
    BREAST JOURNAL, 2020, 26 (05): : 1064 - 1066
12345